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Although the threat for an inﬂuenza pandemic did not appear much in media in 2007, work con-
tinued to convert the National Inﬂuenza Pandemic Plan into plans and practical measures in the 
regional level, primary health care, as well as in other sectors than health care. An EU-WHO eval-
uation of the preparedness in Finland in 2007 stressed the need to bring the planning and action 
to the primary health care level.  The beneﬁts of this preparedness, to a large extent generic for 
all unexpected biothreats, could be seen eg in how the regional and municipal level actors collab-
orated in a major water-borne outbreak of gastrointestinal disease in Nokia (see below).
The structures for infectious disease surveillance, outbreak detection and investigations re-
mained unchanged. To meet the information need in monitoring the effect of the revised (2005 
and 2006) vaccination program, enhanced data collection by the National Infectious Disease Reg-
ister was introduced for childhood whooping cough and tuberculosis, as well as all tick-born en-
cephalitis (TBE) cases.
The European Centre for Disease Control and Prevention (ECDC) in Stockholm continued 
the integration into its organisational structure of EU surveillance coordination, formerly based 
on devolved disease speciﬁc networks. Based on a thorough evaluation of each of the networks, 
some of them will still be coordinated from outside ECDC. From surveillance year 2007 onwards, 
virtually all surveillance data will be sent to a common data base in ECDC. Revised EU surveil-
lance case deﬁnitions were published, which forms the basis on how surveillance data collection 
needs to be implemented in EU Member States. This led to a change in the criteria for registra-
tion for 2007 of tuberculosis cases for statistics in Finland.
GENERAL EPIDEMIOLOGICAL SITUATION IN 2007
Among respiratory infections, legionella cases increased clearly from preceding years. There were 
two international, travel-related incidents in which Finnish travellers were involved. A cluster of 
Pontiac fever, caused by legionella, in a plant reminded of the potential environmental risk spots 
in Finland. The increasing proportion of Legionellosis cases conﬁrmed by urine antigen detection 
suggested that the use of this more sensitive diagnostic method, promoted for some years, is be-
coming more common and making the surveillance system more sensitive to detect outbreaks.
Gastrointestinal infections were dominated by norovirus early in the year and by the water-
borne outbreak of gastrointestinal illness in Nokia in November-December. There was a major 
winter epidemic of norovirus in January to April, involving a large number of institutional out-
breaks, and bringing the annual number of notiﬁed cases to the clearly highest level so far. Much 
of the increase in numbers is due to the fact the use of laboratory diagnostics for norovirus has 
most obviously increased considerably. The outbreak in Nokia, caused by massive accidental mix-
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ing of partially treated sewage into the mains water for distribution, was the largest water-borne 
outbreak in Finland in recent decades, causing several thousand cases of gastrointestinal illness. 
The event has triggered a critical review of the risks in water systems all over Finland. The still on-
going investigations and analyses of collected data will give a comprehensive picture of the conse-
quences of the event to health and economy.
Hepatitis A almost disappeared from the disease panorama in 2007, and acute hepatitis B 
cases fell to one tenth of the ﬁgures ten years earlier. Furthermore, the downward trend in newly 
diagnosed hepatitis C cases continued, particularly in teenagers and young adults. These support 
the perception that the control activities involving increased vaccination (A and B) of travellers and 
speciﬁc risk groups, together with comprehensive measures to reduce intravenous drug abuse and 
the infectious disease harms from it have been effective.
Although there was no clear increasing (nor decreasing) trend for sexually transmitted dis-
eases in 2007, there were features of concern in their epidemiology. Regionally, in the Helsinki met-
ropolitan area there was a major increase in syphilis cases transmitted through sex between men. 
HIV cases remained at the high level of the preceding record year, due to an increase in cases ac-
quired both in heterosex and in sex between men. Although travel-related transmission of syphilis 
and HIV remains important, the risk of contracting these infections in Finland is also real.
For tuberculosis, the favourable downward trend continued, although the total number of 
cases rose slightly due to purely technical reasons, ie revised criteria in registering cases in sta-
tistics. There was no increase in pediatric tuberculosis cases (with comparable registration crite-
ria), which is reassuring after the change in BCG vaccination policy in 2006 from universal to risk-
group vaccination.
Among the indicators for development of the antimicrobial resistance situation, there is cause 
for concern: the total number of MRSA, as well as the proportion of MRSA among invasive iso-
lates of Staphylococcus aureus remain stable, and the proportion of Streptococcus pneumoniae 
with decreased susceptibility to penicillin remained at 14%, but the number of cases with VRE dou-
bled from the preceding year. The combat against resistance needs to be strengthened to improve 
the situation.
Helsinki May 2, 2008
Petri Ruutu
Research Professor
Department of Infectious Disease Epidemiology and Control
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INFLUENZA A
The epidemic in winter 2006–2007 was caused by 
subtype H3N2 viruses, which have typically caused 
clinically severe infections in young children and 
in over 65-year-olds. The proportion of children 
was high in the inﬂuenza A ﬁndings notiﬁed to the 
National Infectious Diseases Register. Under 5-
year-olds accounted for 24 per cent of the cases, 
while only seven per cent of the patients were over 
64 years old. The 15–24-year-olds were a third im-
portant age group with 13 per cent of all the ﬁnd-
ings. Conscripts were overrepresented in this age 
group.  The ﬁrst cases of inﬂuenza were diagnosed 
as early as November–December, but the epidem-
ic did not take off until January, peaking in Febru-
ary–March.  The last, sporadic cases of inﬂuenza A 
were reported in May.
The H3N2 viruses of the season 2006–2007 had 
developed from the Fujian/411/02 virus or its close 
relatives. In the season 2003–2004, the appearance 
of Fujian viruses was a new feature in the antigen-
ic variation of the H3 viruses, and they caused an 
early, intensive epidemic in that season. Antigeni-
cally, the viruses of winter 2006–2007 represent Wis-
consin/67/05 type variants and belong to the same 
genetic lineage as the Wisconsin/67/05 H3N2 virus 
that was included in the vaccine in autumn 2006. At 
least with regard to this subtype, the vaccine was 
constructed correctly. The close relationship of the 
H3 viruses circulating in winter 2006–2007 to the ep-
idemic viruses of the two previous winters explains 
at least partly the limited size of the epidemic, as the 
majority of the population had at least some protec-
tive immunity against these viruses. 
RESPIRATORY INFECTIONS
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Figure 1. Influenza A cases by month, 1995–2007
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Only one case of inﬂuenza A subtype H1N1 
virus, considered typical for children and young 
adults, was diagnosed at the National Public 
Health Institute. The virus was antigenically and 
genetically similar to the Solomon Islands/3/2006 
virus that has been diagnosed elsewhere as well 
and was included in the vaccine in autumn 2007. 
The importance of this variant was not realised 
until after a decision was made in February 2006 
to continue using the New Caledonia/20/99 virus 
in the vaccine to represent the H1N1 viruses. For-
tunately, the H1N1 virus has not caused an exten-
sive epidemic.
INFLUENZA B
The inﬂuenza B epidemic in winter 2006–2007 was 
very mild, and the majority of cases were diag-
nosed as late as March–April. The National Infec-
tious Diseases Register received  107 notiﬁcations, 
representing all age groups. In long-term surveil-
lance, B epidemics have broken out later than A 
epidemics and have been more limited in size. The 
slower variation rate of B viruses and the protec-
tive immunity that has developed in the population 
with time have probably slowed the spread of B 
epidemics more efﬁciently than A epidemics. 
Today, the inﬂuenza B viruses circulating 
the world are divided into two lineages: Yamaga-
ta/16/88 and Victoria/2/87. The autumn 2006 vac-
cine included the Malaysia/2506/04 virus that rep-
resents the Victoria lineage. During the entire 
winter, the National Public Health Institute isolat-
ed an inﬂuenza B virus in two patients only. They 
both represented the Yamagata lineage, which 
means that with regard to inﬂuenza B viruses, the 
choice of vaccine virus was not optimal either. 
RSV (RESPIRATORY SYNCYTIAL VIRUS)
In 2007, National Infectious Diseases Register re-
ceived about 1,600 notiﬁcations of laboratory-con-
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Figure 2. RSV by month, 1995–2007
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ﬁrmed RSV cases (3/100,000), which was about 
the same as in 2004 and 2006. The latest peak was 
observed in 2005 with 2,330 cases. In Finland, 
RSV follows a regular two-year pattern: in uneven 
years there is a limited spring outbreak, followed 
by a more forceful winter outbreak around New 
Year. The 2007 spring outbreak was more inten-
sive than usual, peaking in April. Incidences varied 
by hospital district (6–87/100,000). As in previous 
years, nine out of ten RSV cases were diagnosed 
in 0–4-year-olds. Even though infections occur in 
all age groups, babies and small children consti-
tute the majority of cases leading to hospitalisation 
and laboratory diagnostics (Figure 2). 
LEGIONELLA
In 2007, there were 46 notiﬁed cases of legionella 
based on laboratory ﬁndings, 30 men and 16 wom-
en. Their age ranged from 18 to 79 years. From 
1995 to 2006, the National Infectious Diseases Reg-
ister received about 10–30 notiﬁcations of legionel-
la each year, which makes the 2007 ﬁgure excep-
tionally high. The rise may partly be explained by 
increasing awareness of legionella infections, re-
sulting in more frequent testing for legionella. In 
eight cases, the diagnosis was based on sputum or 
BAL ﬂuid culture or PCR, in eleven cases on detec-
tion of antigen in urine, and the rest were based 
on serological methods. In further investigations, 
the clinical picture was found to be consistent with 
legionellosis in 31 cases, in other words, the pa-
tient had symptom-based or radiologically diag-
nosed pneumonia. All the eleven patients whose 
legionella was conﬁrmed by a urinary antigen test 
had pneumonia. In 2007, one 49-year-old male 
with a severe underlying disease died of legionel-
losis.
About half of the legionellosis patients had 
been abroad prior to becoming ill (and stayed at 
a hotel). The accommodation data of these pa-
tients were reported to EWGLINET (the Euro-
pean Surveillance Scheme for Travel Associ-
ated Legionnaires Disease), which collects data 
on travel-associated legionella ﬁndings. At New 
Year 2006–2007, three Finnish and ﬁve other Nor-
dic tourists contracted legionellosis after staying 
at a hotel in Phuket, Thailand. In June 2007, two 
Finnish and three British tourists staying at a ho-
tel in Sunny Beach, Bulgaria, caught legionello-
sis. It is also possible to become exposed to a le-
gionella infection in Finland. Two men contracted 
a legionella infection on the same occasion from 
a Jacuzzi bath at a sauna; one of them was diag-
nosed with pneumonia. Late in 2007, three em-
ployees at a Finnish chemical plant were diag-
nosed with Pontiac fever, caused by the legionella 
bacterium. 
WHOOPING COUGH (BORDETELLA PERTUSSIS)
In 2007, the number of whooping cough cases no-
tiﬁed to the National Infectious Diseases Regis-
ter totalled 478 (9/100,000), which is slightly below 
the ﬁgure of the preceding year (536 cases). The 
majority of cases were diagnosed based on anti-
body testing. There were 29 ﬁndings (6%) in chil-
dren under 12 months of age, and half of these in 
children under three months of age. As previous-
ly, schoolchildren were the largest patient group. 
About one third of the cases were reported in over 
20-year-olds. There was less variation in preva-
lence between hospital districts than previously 
(3–17/100,000). The incidence was highest in the 
Lappi hospital district and lowest in the Kymen-
laakso hospital district. It can be expected that 
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the booster vaccinations administered to 6-year-
olds since 2003 and to 11-year-olds since 2005 will 
change the epidemiological situation of whooping 
1995 1996 19981997 1999 2000 2001 2002 2003 2004 2005 2006 2007
Figure 3. Whooping cough by month, 1995–2007
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cough in the next few years. The ﬁgures for 2007 
do not yet indicate any signiﬁcant changes in the 
situation (Figure 3).
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SALMONELLA
There were 2,735 cases of salmonella notiﬁed in 
2007 and 2,576 cases in the year before. In 2006 
and 2007 there were more notiﬁed cases than in 
the preceding years. Fifty-four per cent of the 
patients were women. Annual incidence in the 
entire country was 52/100,000 population. The 
incidence rates were highest in the hospital dis-
tricts of Etelä-Savo (89/100,000) and Kanta-Häme 
(69/100,000) and lowest in the hospital districts of 
Keski-Pohjanmaa (31/100,000) and Kymenlaakso 
(37/100,000). The incidence was highest in 20–54-
year-olds (66–85/100,000) and lowest in over-75-
year-olds (9/100,000). 
The most common Salmonella serotypes 
were Enteritidis (796 cases), Typhimurium (396), 
Stanley (175) and Virchow (158). More than one 
INTESTINAL INFECTIONS
salmonella serotypes were diagnosed in 31 cases. 
There were 11 diagnosed cases of S. Typhi, 
which causes typhoid, six cases of S. Paratyphi 
A, which causes paratyphoid, and three cases of 
S. Paratyphi B. Travel data were available for all 
the S. Typhi cases; only one of them had not trav-
elled abroad. All the patients with S. Paratyphi had 
been abroad. S. Typhi and S. Paratyphi were most 
often contracted in India or Thailand. 
There were 380 (14%) salmonella cases ac-
quired in Finland and 2,270 (83%) acquired 
abroad. No country of acquisition was speciﬁed 
in 85 cases (3%). The total number of domestical-
ly acquired infections was similar to the ﬁgure in 
2006 (432 cases), with an incidence of 6/100,000 
inhabitants. S. Typhimurium serotype caused the 
majority of domestic cases (156 cases, 41%), fol-
1995 1996 19981997 1999 2000 2001 2002 2003 2004 2005 2006 2007
Figure 4. Salmonella and Campylobacter cases by month, 1995–2007
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lowed by S. Enteritidis with 62 diagnosed cases. 
The total number of salmonella infections ac-
quired abroad was 2,270 and the incidence was 
39/100,000 population. The S. Enteritidis serotype 
caused 735 (32 %) of the cases with foreign origin. 
Table 1. The most common serotypes of salmonella cases, 1997–2007 
(S. Typhi and S. Paratyphi not included)
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Infections acquired abroad
Salmonella Enteritidis 912 944 892 1046 1238 904 907 774 834 879 735
Salmonella Typhimurium 159 133 103 204 139 115 135 166 194 141 246
Salmonella Virchow 85 82 76 49 79 55 67 74 88 80 135
Salmonella Hadar 57 79 112 125 96 69 58
Salmonella Newport 34 53 66
Salmonella Infantis 67
Salmonella Braenderup 38 49
Salmonella Stanley 62 65 67 105 113 116 175
Salmonella Corvallis 60 59
Other 758 827 680 747 757 636 628 665 654 745 920
Total 2005 2132 1901 2220 2371 1844 1862 1837 1943 2027 2270
Domestically acquired infections
Salmonella Typhimurium 499 222 375 124 152 222 137 131 240 170 150
Salmonella Enteritidis 79 59 83 52 63 42 61 81 75 69 61
Salmonella Hvittingfoss 26
Salmonella Hadar 31 10 17
Salmonella Infantis 24 21 19 10
Salmonella Newport 22 66 16 7 9 12
Salmonella Saintpaul 22
Salmonella Agona 85 27 41 16 12 27 32 40
Salmonella Poona 10 9
Salmonella Virchow 15 11 23
Salmonella Ohio 12
Salmonella Abony 15
Salmonella Stanley 8 5
Salmonella Give 39
Other 153 122 93 90 103 85 75 81 80 98 86
Total 808 512 656 325 390 406 310 335 442 396  372
Country of acquisition not speciﬁed 
Number of cases 233 301 476 223 145 102 107 86 111 153 93 
Total 3046 2945 3033 2768 2906 2352 2279 2258 2496 2576 2735
The next most common serotypes acquired abroad 
were Typhimurium (246 cases), Stanley (175 cases), 
Virchow (135 cases) and Corvallis (59). The leading 
countries of acquisition were Thailand (36%), India 
(8%), Spain (5%) and Bulgaria (5%).
I N F E C T I O U S  D I S E A S E S  I N  F I N L A N D  2 0 0 7
13
Epidemiology of salmonella phenotypes and genotypes
Fifty different serotypes caused domestic salmo-
nella infections. The leading ﬁve serotypes were the 
following: Typhimurium (41%), Enteritidis (16%), 
Agona (11%), Newport (7%) and Stanley (3%). 
Phage type NST (not speciﬁc type) caused the ma-
jority (29%) of domestic Typhimurium cases (156 
cases). Sixty-four per cent of these represented the 
genotype STYM 187 with a new DNA proﬁle, as-
sociated with an outbreak of salmonellosis in the 
Mikkeli region caused by S. Typhimurium. The tra-
ditional endemic phage type FT1 caused 24% of the 
domestic Typhimurium cases. It was distributed to 
six different genotypes. As previously, the major-
ity of cases (81%) represented the genotype STYM 
1, which is susceptible to antimicrobials. More 
than 10% of all domestic Typhimurium cases were 
caused by Typhimurium FT 104, STYM 7, ACSSuT 
(resistant to ampicillin, chloramphenicol, streptomy-
cin, sulphonamide, tetracycline). This is more than 
twice the ﬁgure in 2006, but the majority of cases 
were associated with one outbreak (a day-care cen-
tre in Helsinki). This type of S. Typhimurium is oc-
casionally also isolated from Finnish livestock, but it 
is not known to have a permanent reservoir in Fin-
land. The Enteritidis serotype is not known to have 
a permanent reservoir in Finland either. Neverthe-
less, 62 domestic cases were diagnosed. Forty-sev-
en per cent of them represented the phage type FT 
4 (main genotype SENT 2, reduced susceptibility to 
ﬂuoroquinolones [MIC ? 0.125 mg/L]) and 27% rep-
resented the phage type FT 21 (SENT1, susceptible 
to antimicrobials). 
The salmonella infections acquired abroad 
represented 144 different serotypes. The lead-
ing ﬁve serotypes were the following: Enteri-
tidis (31%), Typhimurium (11%), Stanley (8%, 
mainly from Thailand), Virchow (6%, Thailand, 
India, Gambia, Egypt) and Group B (4%, Thai-
land). The most common Enteritidis phage types 
were FT 1 (23%; 25 different countries, most of 
the DNA proﬁles represented the genotype SENT 
1 or SENT 2), FT 21 (15%; the majority of cases 
acquired in the Mediterranean region; SENT 1, 
SENT 2), FT 4 (14%; Central and Southern Eu-
rope, Estonia; SENT 2, SENT 6), FT 8 (9%; Hun-
gary, Bulgaria, Tunisia; SENT 15). The most com-
mon Typhimurium phage types were FT NST 
(36%; 21 different countries, 16 different geno-
types), FT 120 (14%; mainly Thailand), FT 193 
(9%; mainly Thailand). 
According to “epidemiological” susceptibil-
ity testing involving twelve antimicrobials (sal-
monella strains isolated from 2,460 cases were 
analysed), 9% of Finnish and 15% of salmonel-
las acquired abroad were multiresistant (resist-
ant to at least four antimicrobials). Nalidixic acid 
resistance (Nal R) can be used to predict reduced 
susceptibility (MIC ? 0.125 mg/L) to ﬂuoroqui-
nolones. Thirteen per cent of the domestic strains 
and twenty-two per cent of the strains acquired 
abroad were Nal R strains. More than 90% of 
these strains showed a reduced MIC value to cip-
roﬂoxacin, regardless of whether the strain was 
of domestic or foreign origin. Of all the strains, 
only ﬁve (0.2%) were resistant to cefotaxime; the 
infections were acquired in Thailand, South Af-
rica, Ethiopia and Italy. In addition, eight strains 
had intermediate (I) susceptibility to cefotaxime. 
One of these infections was acquired in Egypt 
and the rest in Thailand. It can be expected that 
the proportion of cefotaxime-resistant strains 
will increase in future, if tourism to Thailand 
maintains its popularity among Finns. 
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CAMPYLOBACTER
In 2007, the National Infectious Diseases Regis-
ter received 4,107 notiﬁcations of campylobacter 
infections. This is 19% (668 cases) higher than in 
2006. Campylobacter jejuni was clearly the pre-
vailing campylobacter species (3,237 cases). There 
were 197 notiﬁed cases of C. coli and 669 un-
typed campylobacter ﬁndings. The incidence rate 
in the entire population was 78/100,000. Fifty-two 
per cent of the patients were men. The incidence 
rate was highest in 25–34-year-olds (161/100,000).  
Helsinki and Uusimaa (122/100,000) and Pirkan-
maa (105/100,000) were the hospital districts with 
the highest incidences. The lowest incidence 
was reported in the hospital district of Åland 
(11/100,000). The seasonal variation was typi-
cal for campylobacter. The incidence was highest 
in July–August. The number of cases reported in 
1995 1996 19981997 1999 2000 2001 2002 2003 2004 2005 2006 2007
Figure 4. Salmonella and Campylobacter cases by month, 1995–2007
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December (480) was more than double compared 
with previous years. The high incidence in Pirkan-
maa and the record number of cases in December 
are explained by a water-borne outbreak in Nokia 
in November–December. In December, Nokia re-
ported 191 campylobacter cases, while there was 
only one reported case in December of the preced-
ing year.
In 3,112 cases (76%) information was ob-
tained about travelling abroad. Seventy-ﬁve per 
cent of these patients had been abroad just prior 
to becoming ill. The leading countries of acquisi-
tion were India (302 cases), Thailand (291 cases) 
and Spain (217) (Figure 4).
YERSINIA
Yersinia enterocolitica
The number of Yersinia enterocolitica cases has 
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1995 1996 19981997 1999 2000 2001 2002 2003 2004 2005 2006 2007
Figure 5. Yersinia enterocolitica cases, 1995–2007
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n
gradually decreased since 1995 (873). After a 
few relatively stable years, the number of cases 
fell by 22% from 2006 (533) to 2007 (414). This 
figure is the lowest in the entire surveillance 
period. In 2007, the incidence rate in the en-
tire country was below 8/100,000. The highest 
incidences were reported in over 75-year-olds 
(15/100,000). There is great regional variation in 
the number of Yersinia enterocolitica findings. 
The incidence was highest in the hospital dis-
trict of Kainuu (26/100,000), while no cases were 
diagnosed in the hospital district of Etelä-Savo. 
(Figure 5).
Yersinia pseudotuberculosis
The number of Yersinia pseudotuberculosis cases 
dropped back to a low level (56 cases) after the high 
ﬁgure (252) in 2006. No distinct trend can be seen 
in the incidence of Y. pseudotuberculosis cases; in 
many years, outbreaks have caused great varia-
tion in the number of cases. In 2007, the incidence 
in the entire country was 1/100,000 population. The 
number of cases is so low that regional differences 
cannot be described; nine hospital districts did not 
report any cases in 2007 (Figure 6).
SHIGELLA
The incidence of shigellosis in 2007 was 
2.1/100,000. There were 112 notiﬁed cases, of 
which 37 were men and 75 women. The incidence 
was highest in 25–49-year-olds. Half of the cases 
(56) were diagnosed in the Helsinki and Uusimaa 
hospital district, which also had the highest in-
cidence rate (4/100,000). There were no cases in 
seven hospital districts. Eighty infections were ac-
quired abroad and twenty-ﬁve in Finland. In seven 
cases the country of acquisition was not speci-
ﬁed. The prevailing shigella species were Shig-
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ella sonnei (58 cases), S. ﬂexneri (26 cases) and S. 
boydii (19 cases). There were only two cases of S. 
dysenteriae. The leading countries of acquisition 
were India (27), Finland (25) and Egypt (11). The 
high number of domestic infections was due to S. 
boydii ﬁndings in Pirkanmaa in connection with 
two individual outbreaks (see the section on out-
breaks).
Eighty-seven per cent of the shigella strains 
were resistant to at least four antimicrobials. Fifty-
one per cent were resistant to nalidixic acid and 
about 89% of these exhibited impaired susceptibil-
ity to ciproﬂoxacin (MIC at least 0.125 mg/L). Nali-
dixic acid resistant strains came mainly from India. 
Among these, the strains with the highest resist-
ance to ciproﬂoxacin (MIC 4–12 mg/L) represent-
ed S. ﬂexner serotype 2a or 3a. Also, the Finnish 
epidemic strain (S. boydii “temporary” serotype 
E140634) showed reduced susceptibility to cipro-
ﬂoxacin.
ENTEROHAEMORRHAGIC ESCHERICHIA COLI EHEC
Twelve microbiologically conﬁrmed cases of enter-
ohaemorrhagic Escherichia coli (EHEC) were no-
tiﬁed to the National Infectious Diseases Register 
(0.2/100,000). The number of cases has remained 
approximately the same in recent years. Seven 
cases were diagnosed in women and ﬁve in men. 
Six patients were under 15 years old, four of them 
0–4 years of age. In one child the infection led to 
HUS syndrome. In seven cases the infection was 
acquired abroad.
O157 serogroup strains caused nine infec-
tions, three of them in one family. In addition, 
there were three individual non-O157 infections, 
one of them acquired abroad.
NOROVIRUS
In 2007 there were 2,790 notiﬁed cases of norovi-
rus, 1,596 of them (59%) in women. The incidence 
rate, 53/100,000, was clearly higher than in the 
1995 1996 19981997 1999 2000 2001 2002 2003 2004 2005 2006 2007
Figure 6. Yersinia pseudotuberculosis cases, 1995–2007
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preceding years. More than 80% of the cases were 
notiﬁed in January–April. More than half (53%) of 
the patients were over 75 years of age with an in-
cidence rate of 379/100,000, but infections were di-
agnosed in all age groups. The highest incidences 
were reported in the hospital districts of Lapland, 
Keski-Pohjanmaa and Helsinki and Uusimaa.
The accumulation of norovirus cases in the 
ﬁrst part of the year was the result of numerous 
institutional outbreaks that began to occur at the 
end of 2006, particularly in hospitals and old peo-
ple’s homes. This also explains the high incidence 
rate in the elderly and the considerable regional 
variation. In the background of these outbreaks 
was the emergence of new genotype GII.4 norovi-
rus variants (GII4-2006a and GII4-2006b). During 
the winter, the proportion of GII4-2006a decreased 
and GII4-2006b became dominant. In December 
2007, there was another sharp upward turn in the 
number of cases. This was due to numerous insti-
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Figure 7. Norovirus cases by month, 2005–2007
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tutional outbreaks caused by the GII4-2006b vari-
ant. In addition to this dominant variant, infections 
caused by the GI.1, GII.7 and GI.3B variants were 
diagnosed during the autumn. The GI1 variant, 
which does not normally cause hospital outbreaks, 
caused an outbreak in wedding guests in Northern 
Finland in September. In the latter part of the year, 
the outbreaks caused by the GII.7 variant includ-
ed a long-lasting outbreak in a garrison in Central 
Finland.
ROTAVIRUS
In 2007 there were 973 notiﬁed rotavirus cas-
es, with an incidence of 19/100,000. Of these, 522 
cases were diagnosed in men and 451 in women. 
The number of cases was clearly the lowest in the 
2000s so far. The monthly variation of incidence 
rates followed the normal pattern: the number of 
cases rose during spring, peaked in April and de-
creased in June–July. The incidence was clear-
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ly highest in children under ﬁve years of age 
(312/100,000). They constituted 91 per cent of all 
cases. All hospital districts notiﬁed cases. The in-
cidence rate was highest in the Lappi hospital dis-
trict (84/100,000). In all the other hospital districts, 
the incidence rate remained below 36/100,000, in 
some hospital districts even considerably lower 
than this. These are interesting times with regard 
to the rotavirus, as the ﬁrst rotavirus vaccine was 
licenced in Finland in the summer of 2006. At ﬁrst 
the vaccine was used sporadically, but the use in-
creased vigorously in 2007. Based on sales ﬁgures, 
nearly one out of three newborn babies received a 
rotavirus vaccination in 2007.
LISTERIA
Forty Listeria monocytogenes infections were no-
tiﬁed in 2007. Fifty-three per cent of the patients 
were men and seventy per cent were 65 years 
of age or older. The annual incidence of listerio-
sis was 7.5 cases per million population. There 
were 36 blood ﬁndings (90%) and three CSF ﬁnd-
ings. One ﬁnding was obtained from other punc-
ture samples. One patient died. None of the cases 
were associated with pregnancy, and only one of 
the patients was a child. Listeriosis was diagnosed 
in nearly all hospital districts, with the number of 
cases ranging from zero to seven. Serotype 1/2a 
caused 58 per cent of the infections, and serotype 
4b caused 30 per cent. 
SIGNIFICANT FOOD- AND WATER-BORNE OUT-
BREAKS
In 2007, the National Public Health Institute re-
ceived 55 notiﬁcations of suspected food- or wa-
ter-borne outbreaks. They included an extensive 
water-borne outbreak in Nokia with several diag-
nosed pathogens, and an outbreak of gastrointes-
tinal illness caused by Shigella boydii at the Tam-
pere Hall. Several other gastrointestinal infection 
clusters were investigated as well.
Water-borne outbreak in Nokia
At the end of November (28–30 November, 
2007), about 400,000 litres of treated waste wa-
ter leaked into the clean water supply in the city 
of Nokia. The leakage was noticed on Friday, 
30 November 2007, and the residents of Nokia 
were told to boil their drinking water. The con-
tamination of the water resulted in an extensive 
outbreak of gastrointestinal illness. More than 
1,000 persons sought care at the health centre 
or the hospital emergency department. The in-
patient ward of Nokia Health Centre treated 51 
patients and the Tampere University Hospital 
treated 185 patients, 126 of them children. The 
main pathogens were norovirus and Campylo-
bacter, but Salmonella, Giardia, rotavirus, Shig-
ella boydii and Clostridium difficile were de-
tected in patients as well. Water samples also 
contained a wide range of microbes that mostly 
matched those found in the patients. The out-
break was exceptional in its extent, and the 
number of microbes found was unusual. Do-
mestic water outbreaks usually involve only one 
pathogen, even though the samples collected 
from patients are always analysed for all of the 
most common bacteria causing gastrointestinal 
illness (campylobacters, salmonellas, yersinias, 
shigellas) and often also for the most common 
viruses (norovirus, rotavirus, adenovirus).
The National Public Health Institute, Pirkan-
maa Hospital District, City of Nokia and University 
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of Tampere conducted a survey to analyse overall 
morbidity, complications, costs and psychological 
effects on the population. The questionnaire was 
sent to 3,000 persons in Nokia and in Kangasa-
la, which was selected as a control municipality. 
Tampere University Hospital conducted additional 
surveys to investigate complications related to the 
outbreak.
Shigella boydii in Tampere
The Tampere Hall hosted a Red Cross emergency 
care symposium from 19 to 20 November 2007. 
About 400 people from all around Finland attend-
ed the symposium, and some of them fell ill with 
gastrointestinal illness already in the afternoon of 
November 19. Eighteen culture-conﬁrmed cases 
of S. boydii were diagnosed during the outbreak. 
A questionnaire survey was conducted. Of the 
223 participants who completed the question-
naire, 90 had fallen ill with gastrointestinal ill-
ness between November 19 and 25.  Based on the 
questionnaire survey, no food served at the sym-
posium could be identiﬁed as a possible cause 
for the outbreak. No shigella was detected in the 
samples collected from the kitchen staff and wait-
ers, and their interviews did not reveal any trips 
abroad with the possibility of contracting a shig-
ella infection. The cause of this outbreak is rare 
in Finland, and the mechanism of infection re-
mained unclear despite extensive investigations. 
The same uncommon S. boydii (“provisional se-
rotype E140634”) strain was later diagnosed in 
some patients during the water outbreak in No-
kia. The strains were conﬁrmed in the interna-
tional reference laboratory of HPA (Health Pro-
tection Agency) in England.
Salmonella Weltevreden
Four Salmonella Weltevreden infections were di-
agnosed in Norway between 10 and 15 October 
2007 in patients with no preceding history of trav-
elling abroad. The outbreak resulted in an inquiry 
that covered all the EU countries. It revealed that 
infections caused by this salmonella serotype had 
been diagnosed in Finland and Denmark as well. 
A few days later in Denmark, S. Weltevreden was 
isolated from alfalfa seeds. MLVA and PFGE anal-
yses showed it to be identical with the human ﬁnd-
ings (DNA proﬁle SWEL 4). A total of 45 persons 
fell ill during the outbreak, 20 of them in Norway, 
19 in Denmark and eight in Finland. Alfalfa shoots 
from the same producer, already withdrawn from 
the market, were analysed in Finland as well, and 
an identical S. Weltevreden was isolated. The 
shoots had come to Finland from a Dutch supplier 
and were probably of Italian origin. 
Salmonella Newport (genotype SNWP 55)
Salmonella Newport was the cause of gastrointes-
tinal illness in 25 people in different parts of Fin-
land in November–December 2007. Disease clus-
ters occurred in Rauma, Lappeenranta, Tampere, 
the Oulu region and the Helsinki region. In Rauma 
and Lappeenranta, the common factor was mass 
catering: in Rauma it was the food supplied by the 
municipal central kitchen and in Lappeenranta the 
food supplied by a sheltered home.  There were no 
children among the patients.
The S. Newport strains found in the patients 
had identical DNA proﬁles. This type had never 
before been found in humans or animals, neither 
in Finland nor abroad. The outbreak was micro-
biologically interesting, because some of the epi-
demic strains formed colony types that represent-
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ed two antigenic structures (S. Newport’s normal 
O:6+ form and the O:6- form). Had this been an 
individual infection, the O:6 negative would have 
been speciﬁed as S. Bardo. The outbreak was in-
vestigated by interviewing patients, and tracing 
back and testing the food that had been served. 
However, the vehicle could not be identiﬁed. 
Salmonella Newport (genotype SNWP 45)
A cluster of ﬁve Salmonella Newport cases was de-
tected in Helsinki in December. The interviewed 
patients had attended the same event at the begin-
ning of December. The DNA proﬁle of the epidem-
ic strain was completely different from that of the 
S. Newport epidemic strain described above.
Salmonella Typhimurium FT 104 
In April, fifteen S. Typhimurium infections were 
detected at a day care centre in Helsinki. The 
phage type of the epidemic strain was FT 104, 
resistance profile ACSSuT (ampicillin, chloram-
phenicol, streptomycin, sulphonamide, tetracy-
cline) and DNA profile STYM 7. The salmonella 
type in question is often found in persons who 
have been in Spain. One of the children had vis-
ited Spain. 
Salmonella Typhimurium FT NST
In July, eight S. Typhimurium infections were di-
agnosed in the Mikkeli region. The source of infec-
tion was not identiﬁed. Twenty persons altogether 
became ill with gastrointestinal illness in Mikkeli in 
August at a workplace party and in September at 
a funeral. S. Typhimurium was found in stool sam-
ples in all the patients. It was susceptible to anti-
microbials. Also, the phage type (NST, not specif-
ic type) and DNA proﬁle (STYM 187) of the strains 
were identical with the July strain. The same ca-
tering service supplied food to both occasions, but 
the food that caused these infections could not be 
identiﬁed in the investigations. The catering serv-
ice employee tested negative for salmonella. 
Salmonella Enteritidis in a formula race 
A number of spectators became ill during the For-
mula 1 race in Hungary between 3 and 5 August 
2007. Salmonella Enteritidis FT 8 was found in pa-
tient samples. There were several dozen patients, 
22 of them Finns. The other nationalities included 
Hungarians, Swedes, Norwegians, Dutchmen and 
Austrians. Outbreak investigations revealed that 
most of the patients had eaten at the same buf-
fet on 3–4 August 2007, and almost all of them had 
eaten chicken. The food served on these particular 
days was no longer available for analysis, but Sal-
monella Infantis grew in the broiler samples col-
lected on 5 August. Stool samples from 21 symp-
tom-free restaurant employees were analysed as 
well; S. Enteritidis FT 8 was found in 12 employ-
ees. 
Salmonella Agona at two conﬁrmation parties
Twelve cases of Salmonella Agona were diagnosed 
in June. They were associated with a conﬁrmation 
party held in Tampere. The epidemic strain was 
susceptible to antimicrobials, and its DNA proﬁle 
was SAGO 39. A cluster of 15 cases caused by a 
similar strain was diagnosed in Loppi in July–Au-
gust. The cases were again associated with a con-
ﬁrmation party. 
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HEPATITIDES
HEPATITIS A
In 2007, the National Infectious Diseases Regis-
ter received 17 notiﬁcations of hepatitis A (inci-
dence 0.3/100,000), which is the lowest ﬁgure ever. 
Twelve patients were men and ﬁve were women. 
Most cases (12) were diagnosed in the HUS dis-
trict, while sixteen hospital districts had no diag-
nosed cases. The highest number of cases, eight, 
was diagnosed in the age group of 15–29-year-
olds. Seven infections were acquired abroad and 
six in Finland. In four cases the country of acquisi-
tion was not speciﬁed. Two Finnish patients con-
tracted the infection from a close relative who had 
taken ill after travelling abroad. 
The incidence of hepatitis A has remained 
low after the epidemics among injecting drug us-
ers in 2002–2003 and is still falling, possibly be-
cause of vaccinations targeted at risk groups and 
travellers. The family of a hepatitis A patient must 
always be protected by gamma globulin or vacci-
nation.
HEPATITIS B
In 2007, only 23 acute hepatitis B cases were noti-
ﬁed to the National Infectious Diseases Register, 
which is less than a tenth of the top ﬁgure in 1997. 
In 2007 there were no signs of  clusters that have 
been described in previous years. 
Fourteen of the patients were men and nine 
were women. The majority of cases (12) were di-
agnosed in the Helsinki and Uusimaa hospital dis-
trict. Twelve hospital districts had no diagnosed 
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Figure 8. Acute Hepatitis B cases, injecting drugs and sexually transmitted infections, 1998–2007
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cases. The number of infections has continued to 
fall among young and middle-aged adults.
It seems that including hepatitis B vaccina-
tions in the general vaccination programme for risk 
groups, as well as the health counselling for inject-
ing drug users and the adverse effect prevention 
work have had the desired results (Figure 8, Table 
2). Only one case of acute hepatitis B associated 
with injecting drug use was diagnosed in 2007.
HEPATITIS C
The number of hepatitis C cases continued to de-
crease in 2007, albeit slowly. Nevertheless, the de-
crease continues, and closer examination of the 
ﬁgures reveals some positive trends. It is difﬁcult 
to separate acute hepatitis C infections from those 
acquired years ago, which is why any changes in 
the ﬁgures should be interpreted cautiously. The 
prevalence of hepatitis C is so high among inject-
ing drug users that changes in prevalence are very 
slow, even if the risks were well under control. 
Most of the cases with an identiﬁed source 
of infection are associated with injecting drug use 
(Table 3). The number of these cases has been de-
creasing throughout the 2000s (928 cases in 2000, 
571 cases in 2006; the decreasing trend seems to 
continue in 2007). At the same time, the number of 
cases with unknown origin has decreased less rap-
idly (708 cases in 2000, 486 in 2006). This suggests 
that the decrease is real and not, for example, a 
result of doctors reporting the source of infection 
less frequently than before.
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Injecting drugs 76 107 82 28 43 18 8 3 4 1
Sex 45 36 39 41 37 19 16 10 15 7
Perinatal 1 1 1 - 1 1 - - - -
Blood products 4 1 1 1 1 - 3 - - -
Other 4 9 8 6 2 1 4 3 2 1
Unknown 116 103 109 51 93 67 28 18 16 14
Total 246 258 240 127 177 106 59 34 37 23
Table 2. Acute Hepatitis B cases by mode of transmission from physician notiﬁcations, 1998–2007*)
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Injecting drugs 1047 1001 928 822 710 627 603 621 571 416
Sex 55 35 41 42 45 46 59 61 70 63
Perinatal 4 10 6 3 3 1 10 5 8 4
Blood products 27 23 25 19 18 22 18 24 7 17
Other 24 40 31 31 28 34 31 35 37 23
Unknown 646 643 708 574 567 533 517 497 486 634
Total 1803 1753 1739 1492 1372 1264 1238 1244 1181 1157
Table 3. Hepatitis C cases by mode of transmission from physician notiﬁcations, 1998–2007*)
*) Between 1995-2003 four HBV cases have been notiﬁed to have been transmitted by Finnish blood products. Since 2000 no cases of HCV transmit-
ted by Finnish blood products have been notiﬁed. The surveillance for the mechanism of transmission for HCV was started in 1998.
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Figure 9. Hepatitis C cases by age, 1998–2007
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With regard to age groups, the number of 
HCV cases among 15–19-year-olds has fallen by 
more than half since 2002 (Figure 9). There are 
signs of a decrease among 20–24-year-olds as 
well.  In older age groups the number of cases 
has fallen less drastically. This may suggest that 
the health counselling and adverse effects pre-
vention work targeted at injecting drug users 
have been so successful in infection risk preven-
tion that an HCV infection is acquired later in life 
than before, if the drug use continues for a long 
time. It seems that the health counselling provid-
ed for injecting drug users and the adverse effect 
prevention work has had the best results in the 
youngest age groups, which was one of the main 
goals.
As regards the regions of Finland, the inci-
dence rates of HCV have decreased in the prov-
inces of Western, Eastern and Southern Finland. 
However, in the provinces of Oulu and Lapland the 
incidence rates nearly doubled in 2007 compared 
with the previous year (25 and 33 cases /100,000, 
respectively).
Because of the high incidence in Northern 
Finland, health counselling to injecting drug users 
should be increased to cut the infection rates.
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CHLAMYDIA (CHLAMYDIA TRACHOMATIS)
There were 13,973 notiﬁed cases of chlamydia in 
2007 which is about the same as in 2006 (13,854). 
The incidence was 266/100,000. As earlier, the 
highest incidences were reported in the hospi-
tal districts of Åland (299/100,000) and Lapland 
(428/100,000).
Fifty-nine per cent of the patients were wom-
en. The majority of cases were diagnosed in 15–24-
year-old women and 20–24-year-old men. As pre-
viously, in the age group of under 20-year-olds 
women constituted a remarkably larger group of 
patients (2,652) than men (772) (Figure 10).
SEXUALLY TRANSMITTED DISEASES
GONORRHOEA (NEISSERIA GONORRHOEAE) 
The National Infectious Diseases Register received 
193 notiﬁcations of gonorrhoea. The number fell 
slightly compared with the previous year. Eighty-
two per cent of the patients were men. The majori-
ty of patients were 20–55 years of age. The country 
of acquisition was speciﬁed in 76 per cent of infec-
tions. A decrease was seen in the number of  infec-
tions acquired abroad. In 52 per cent of cases with 
a speciﬁed country of acquisition it was other than 
Finland. In 37 cases the infection was acquired in 
the Far East (31%). Six women had acquired the 
infection abroad.
lkm
Figure 10. Chlamydia by age groups in young adults, 1995–2007
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Table 4. Gonorrhea infections acquired domestically and abroad, 1995–2007
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Domestically 
acquired infections
185 83 94 100 108 129 113 100 89 133 132 112 75
Russia 70 50 42 49 42 48 34 28 9 7 23 12 5
Estonia 26 9 7 9 8 7 3 5 2 6 1 1
Thailand 9 9 7 16 19 18 17 31 27 38 30 42 41
Other 25 20 19 24 16 32 26 18 21 21 20 25 21
Place of acquisition 
unknown
63 55 49 71 62 50 54 53 41 47 34 45 50
Total 378 226 218 269 255 284 247 235 189 252 240 236 193
SYPHILIS (TREPONEMA PALLIDUM )
There were 184 notiﬁed syphilis cases in 2007. 
The ﬁgure was higher than in 2006 (130). Sixty-
six per cent of the cases were diagnosed in men. 
Fifty-seven per cent of all cases were diagnosed 
in 25–50-year-olds. The incidences were high-
est in the hospital districts of Helsinki and Uusi-
maa (8.0/100,000), Etelä-Karjala (6.2/100,000), Ky-
menlaakso (4.9/100,000) and Kainuu (4.9/100,000). 
In the Helsinki and Uusimaa hospital district, the 
number of syphilis infections diagnosed in men 
nearly tripled from the previous year.
The country of acquisition was speciﬁed in 
59 per cent of men’s infections, and in 41 per cent 
of these the infection was acquired abroad, most 
often in Russia (8). The country of acquisition was 
reported in 38 per cent of women’s infections. 
Nine women had acquired the infection in Finland 
and ﬁfteen abroad, most often in Russia (Table 5).
HIV INFECTION
In 2007, nearly as many HIV cases were diagnosed 
as in the previous year when the number of cases 
increased by about forty per cent. There were 191 
new diagnosed cases, 130 of them in Finns. The 
increase is due to the rise in sexually transmitted 
HIV infections that has continued throughout the 
2000s. Meanwhile, the number of infections trans-
Table 5. Syphilis infections acquired domestically and abroad,1995–2007
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Domestically ac-
quired infections
48 53 50 46 21 54 31 24 30 22 25 20 51
Russia 49 57 48 33 43 80 49 21 18 16 22 17 15
Estonia 5 11 5 5 3 3 2 1 6 1 6 3 4
Somalia 1 2 5 2 1 2 2 3 3 2
Thailand 1 1 4 1 1 1 2 1 1 2
Other 9 12 14 13 14 17 11 12 14 12 16 17 21
Place of acquisition 
unknown
56 85 52 81 57 49 64 68 62 56 71 70 89
Total 168 219 172 187 140 204 159 128 133 109 144 131 184
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mitted via injecting drugs has remained low. Ten 
cases in this category were diagnosed in 2007, 
only four of them in Finns.
Among Finns, sexually transmitted HIV in-
fections have increased among men having sex 
with men as well as among heterosexuals. In both 
transmission categories, the number of cases has 
more than doubled since the beginning of the 
2000s. This may be a sign of not realising the im-
portance of safe sex or not understanding that 
everyone is at risk. The majority of sexually trans-
mitted HIV infections in Finns are today acquired 
in Finland. Thus, the risk of contracting a sexually 
transmitted HIV infection in Finland has not de-
creased, quite the contrary.
Travel-related risks are still considerable: of 
the 130 infections contracted by Finns, 40 were 
probably acquired abroad. The majority of pa-
tients who acquired their infection abroad were 
men. About ﬁfty per cent of them were heterosex-
Figure 11. Hiv cases detected among immigrants and Finns, 1980–2007
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ual and ﬁfty per cent were men having sex with 
men. As regards heterosexual men, the nearby 
regions now constitute a more signiﬁcant source 
of infections than Southeast Asia, while men hav-
ing sex with men contract travel-related infections 
most often in Western Europe.
Four Finns had contracted  HIV infection 
through injecting drug use. In two of these patients, 
the subtype of the viral strain suggests an infection 
acquired in Finland, while Estonia is the probable 
country of acquisition in the other two cases. Risks 
have increased in this group in Russia and Esto-
nia but also in Stockholm, where a clear rise in the 
number of infections was seen in 2007, with an out-
break among injecting drug users. Based on pre-
liminary information, the outbreak in Stockholm is 
caused by the same CRF01-AEﬁn strain detected in 
the earlier epidemic among injecting drug users in 
Finland. Sweden provides syringe exchange servic-
es only in a few cities in Southern Sweden.
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MRSA
In 2007, the situation with methicillin-resistant 
Staphylococcus aureus (MRSA) remained stable. 
Almost 1,300 cases of MRSA were notiﬁed to the 
National Infectious Diseases Register (1,317 in 
2006). There were 32 MRSA ﬁndings from blood 
(36 cases in 2006) and no ﬁndings in cerebrospinal 
ﬂuid. Fifteen MRSA ﬁndings from blood occurred 
in the Pirkanmaa hospital district (3.2/100,000) and 
seven in the Helsinki and Uusimaa hospital district 
(0.5/100,000). The other hospital districts notiﬁed 
one or two cases each, totalling seven. As earlier, 
the highest ﬁgures were seen the hospital districts 
of Helsinki and Uusimaa and Pirkanmaa. However, 
incidences per 100,000 population were highest in 
the hospital districts of Western Bothnia, Pirkan-
ANTIMICROBIAL RESISTANCE
maa and Northern Karelia. As earlier, the major-
ity of the patients were over 75 years of age. Chil-
dren constituted less than 5 % of all cases MRSA, 
and the number of children’s infections did not in-
crease from the previous year.
The National Public Health Institute’s Labo-
ratory of Hospital Bacteriology conﬁrms and types 
all MRSA strains in Finland. In 2007, the labora-
tory tested a total of 1,366 strains, which is slight-
ly less than in 2006. Approximately 30 per cent of 
the conﬁrmed MRSA infections were still caused 
by one multiply resistant epidemic strain (FIN-16) 
that has been causing problems for years. Other 
epidemic strains observed in previous years (FIN-
4, FIN-7 and FIN-10 clones) were also common 
in many hospital districts. The number of infec-
Figure 12a. MRSA cases by hospital district, 1995–2007
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Figure 12b. MRSA cases by hospital district, 1995–2007
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Table 7. MRSA-ﬁndings and their proportion of Staphylococcus aureus blood culture ﬁndings 
in 1995–2007
Year All MRSA-ﬁndings S. aureus –ﬁndings from 
blood
MRSA-ﬁndings in blood 
and their proportion of 
all S. aureus ﬁndings from 
blood (%)
1995 89 627 2 (0,3)
1996 108 667 0  (0)
1997 120 747 4 (0,5)
1998 189 717 5 (0,7)
1999 211 812 8 (1,0)
2000 261 849 4 (0,5)
2001 340 887 4 (0,5)
2002 599 988 10 (0,9)
2003 851 978 7 (0,7)
2004 1460 1057 32 (2,9)
2005 1368 1013 27 (2,7)
2006 1317 1239 36 (2,9)
2007 1285 1178 32 (2,7)
Total 8198 11759 171 (1,5)
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tions caused by the second most common strain 
in 2005 (FIN-21) fell clearly for the second year in 
a row.  While the FIN-21strain represented 20 per 
cent of the cases in 2005 and about 10 per cent of 
the cases in 2006, its proportion fell to 4 per cent 
of all strains in 2007. Among the ﬁfteen most com-
mon MRSA strains three were Panton-Valentine 
leukocidin (PVL) producing MRSA strains (FIN-
25 , FIN-11 and FIN-5). Five new epidemic strains 
were detected in 2007. Two of these (FIN-37 and 
FIN-39) were among the ﬁfteen most common 
MRSA strains. FIN-16 caused almost half of all the 
MRSA ﬁndings in blood (13 cases). The rest of the 
MRSA ﬁndings in blood represented eight differ-
ent strains (1–4 cases per strain).
VRE
In 2007, the number of vancomycin-resistant en-
terococcus (VRE) ﬁndings notiﬁed to the National 
Infectious Diseases Register doubled from the pre-
vious year. The majority of cases occurred in the 
Northern Bothnia hospital district. The frequency 
of ﬁndings was highest early in the year, and most 
of the patients were 75 years of age or older. In the 
other hospital districts (n=6) the number of ﬁndings 
varied from one to seven. There were three VRE 
ﬁndings in blood and none in cerebrospinal ﬂuid.
In 2007, the National Public Health Institute’s 
Laboratory of Hospital Bacteriology conﬁrmed a 
total of 60 new VRE ﬁndings in 57 persons by bac-
terial typing. Nearly all the ﬁndings represented 
the E. faecium species and the vanB type. The ma-
jority of the ﬁndings (n=44) represented the VRE 
IV strain detected in the Pohjois-Pohjanmaa dis-
trict in previous years, and the rest (n=16) were 
unique ﬁndings or sporadic, previously identiﬁed 
VRE epidemic strain types.
INVASIVE PNEUMOCOCCAL DISEASE (STREPTO-
COCCUS PNEUMONIAE)
The number of notiﬁed cases of invasive pneu-
mococcal disease totalled 788 (15/100,000) in 
Table 8. Antimicrobial resistance of Streptococcus pneumoniae ﬁndings in blood and CSF, 
1998–2007
I= reduced susceptibility; R – resistant; Multidrug resistance – strains simultaneously resistant to penicillin, erythromycin and tetracyclin
Year Cases notiﬁed to 
the National In-
fectious Diseases 
Register
Strains examined Erythomycin 
(%)
Penicillin (I+R) 
(%)
Multidrug resist-
ance (%)
1998 561 84 3,6 0 0
1999 568 471 5,9 7,2 0
2000 601 439 8,0 3,7 1,4
2001 658 360 18,8 7,5 5,0
2002 599 594 16,3 8,0 3,7
2003 721 739 21,9 12,7 5,7
2004 748 748 20,5 9,6 3,7
2005 735 731 20,5 9,6 4,4
2006 741 760 27,9 16,4 5,4
2007 788 794 23,2 14,4 3,5
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2007. The incidence rose slightly from last year 
(14/100,000). 
In 2007, the National Public Health Institute’s 
Antimicrobial Research Laboratory analysed the 
antimicrobial susceptibility of 794 pneumococ-
cal strains isolated from invasive infections. Com-
pared with the year 2006, the proportion of strains 
with decreased susceptibility to penicillin (MIC? 
0.125 μg/ml)fell by two percentage points (14%). The 
proportion of resistant strains (MIC ? 2 μg/ml) was 
1.5 per cent, and 13 per cent of the strains had de-
creased susceptibility (I, intermediate). The propor-
tion of macrolide resistant strains decreased as well; 
23 per cent of invasive pneumococcal strains were 
resistant to erythromycin. The proportion of multi-
ply resistant (PEN-ERY-TET) strains in 2007 was 3.5 
per cent. Fluoroquinolone resistant and ceftriaxone 
resistant strains were not detected in 2007.
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TUBERCULOSIS – MYCOBACTERIUM TUBERCULOSIS
The registration of tuberculosis cases in Finland 
changed in 2007 due to the new case deﬁnitions by 
EU. As a consequence, the number of tuberculosis 
cases increased as compared with the preceding 
year. If the case deﬁnitions of the previous years 
had been applied, the decline in the number cases 
would have continued in 2007.
Between 1995 – 2006 the following cases 
were registered in the statistics: all culture –con-
ﬁrmed cases and, in addition, those cases notiﬁed 
by physicians only, for which the sputum smear 
for acid fast bacilli was been positive or histologi-
cal evidence of tuberculosis was notiﬁed.
MYCOBACTERIAL INFECTIONS
From 2007 also those cases are registered, in 
which the physician clinically suspected tubercu-
losis and decided to give a full tuberculosis treat-
ment, even if tuberculosis had not been conﬁrmed 
by microbiological tests or histology. The added 
criterion for registration does not inﬂuence the 
number of those cases for which the registration is 
based on laboratory tests or histology.
With the new criteria for registration, there 
were 324 tuberculosis cases in 2007, 11 % more 
than in 2006 (291). Tuberculosis incidence was 
6,1/100 000.  If the criteria of the preceding years 
had been applied, the number of cases would have 
been 272 (7 % less than in 2006), continuing the 
Year Pulmonary tuberculosis Other tuberculosis All cases
Cases Cases / 
100 000
Cas-
es with 
positive 
sputum 
smear
Cases with 
positive 
sputum 
smear / 
100 000
 Cases Cases / 
100 000
Cases Cases / 
100 000
Culture-
con-
ﬁrmed 
cases
Propor-
tion of 
culture-
con-
ﬁrmed 
cases 
(%)
1995 435 8,5 243 4,8 227 4,5 662 13 472 71,3
1996 432 8,4 241 4,7 213 4,2 645 12,6 510 79,1
1997 363 7,1 188 3,7 212 4,1 575 11,2 435 75,7
1998 397 7,7 201 3,9 231 4,5 628 12,2 491 78,2
1999 382 7,4 180 3,5 183 3,5 565 11 487 86,2
2000 370 7,2 227 4,4 167 3,2 537 10,4 451 84
2001 315 6,1 158 3 178 3,4 493 9,5 411 83,4
2002 296 5,7 138 2,7 176 3,4 472 9,1 391 82,8
2003 291 5,6 148 2,8 121 2,3 412 7,9 347 84,2
2004 230 4,4 127 2,4 101 1,9 331 6,3 286 86,4
2005 263 5 135 2,6 98 1,9 361 6,9 316 87,5
2006 209 4 98 1,9 82 1,6 291 5,5 265 91,1
2007 225 4,3 91 1,7 99 1,9 324 6,1 245 75,6
Table 6. Incidence of tuberculosis in Finland, 1995–2007
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long-lasting decline in the number of cases. In 
2007, there were 245 culture-conﬁrmed cases, 8 % 
less than in 2006 (265). Based on physician notiﬁ-
cations, 11 (3 %) cases had earlier had tuberculosis 
since 1950, when antituberculosis chemotherapy 
was introduced.
Based on the new criteria for registration, 
there were 225 pulmonary tuberculosis cases 
(4,3/100 000) and 99 cases of other forms of tuber-
culosis. The physicians notiﬁed a positive sputum 
smear for acid fast bacilli in 91 pulmonary tuber-
culosis cases (40 %).
Out of all tuberculosis cases, 4 (1 %) were 
notiﬁed in the age group less than 15 years old, 
44 (14 %) in the age group 15–29 years, 38 (12 %) 
in the age group 30–44 years, 70 (22 %) in the age 
group 45–59 years, 70 (22 %) in the age group 60 
–74 years and 98 (29 %) in those aged 75 years or 
more. In 2007, the median age of all cases was 61 
years. The median age of cases born in Finland 
was 69 years. 
In 2007, 73 (23 %) cases were notiﬁed in per-
sons born abroad or with a nationality other than 
Finland. Among them, three (4 %) were less than 
15 years of age and 58 (79 %) aged 15-44. Fortysix 
(63 %) of the cases were pulmonary and 27 (37 %) 
other forms of tuberculosis.
The susceptibility status of Mycobacterium 
tuberculosis isolates continues to be good. In 2007, 
one (0,4 %) multiresistant (MDR, resistant at least 
to isoniazide and rifampin) strain of M. tuberculo-
sis was isolated in a person with Russian origin.
Among the tuberculosis cases in 2007, 10 (3 
%) also had HIV infection. In four cases, both in-
fections had been notiﬁed for the ﬁrst time in 2007.
Findings from epidemiological typing
In ﬁve cases, genotyping was carried out to in-
vestigate whether the infection was caused by a 
strain previously isolated from the same patient, 
ie relapse, or from infection originating from an-
other source. In all ﬁve cases, identical genotypes 
proved the recent disease to be due to a relapse.
In six instances, involving a total of 18 bacte-
rial strains, possible associations between cas-
es were investigated. In four instances, an asso-
ciation could be excluded. In two instances, both 
from the capital region, the isolates had identical 
genotypes proving a probable transmission chain.
In ﬁve cases, laboratory contamination was 
suspected: in three cases this turned out to be like-
ly, and in two cases contamination was excluded.
Mycobacterium bovis BCG 
In 2007, one culture ﬁnding of Mycobacterium bo-
vis BCG was notiﬁed in the age group less than 15 
–years-old. 
Between 1995-2002, one to ﬁve M. bovis BCG 
culture ﬁndings were annually notiﬁed in children 
less than 15 years old. The number increased to 30 
in 2003 and remained on a level higher than in ear-
lier years (13 in 2004, 23 in 2005, and 13 in 2006).
M. bovis BCG is an attenuated bacterial 
strain developed from M. bovis, which belongs to 
the M. tuberculosis -complex. It is used as the BCG 
vaccine in infants to prevent serious forms of tu-
berculosis in small children. The attenuated strain 
does not cause tuberculosis. In Finland, BCG vac-
cinations were targeted since September 1, 2006, 
to children, who have an increased risk of con-
tracting tuberculosis.
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HAEMOPHILUS (HAEMOPHILUS INFLUENZAE)
In 2007, there were 54 notiﬁed Haemophilus inﬂu-
enzae infections diagnosed in blood or cerebrospi-
nal ﬂuid. Haemophilus inﬂuenzae type b caused an 
infection in four adults and two children. One of 
the children was a ﬁve-year-old unvaccinated child 
of foreign birth visiting Finland, and the other was 
a Finnish infant under three months of age. Since 
1986, children born in 1985 or later have received 
Hib vaccine at the child welfare clinic. Since the be-
ginning of 2005, according to the revised vaccina-
tion programme, Hib vaccination is administered as 
a component of the combination vaccine at the age 
of three, ﬁve and twelve months. The efﬁciency of 
the vaccination is monitored, and vaccination data 
are investigated for all children diagnosed with Hib.
 MENINGOCOCCUS (NEISSERIA MENINGITIDIS)
There were 43 meningococcal infections diag-
nosed in blood or cerebrospinal ﬂuid, which is 
similar to previous years.  The serogroup distribu-
tion was the same as before. The majority of in-
fections were caused by group B meningococcus. 
There were ﬁve group Y strains and eight group 
C strains. In one case the serogroup was uniden-
tiﬁable. Six cases were 0–4 years old and fourteen 
were 15–19 years of age. 
In March 2007, three 18–20-year-old men in 
Kangasala contracted a group B meningococcal 
infection of the same subtype. In September in Im-
atra, one 3-year-old child in day care and one 14-
year-old schoolchild contracted  meningococcal 
infection. Based on the typing data, the infection 
in the 3-year-old was caused by a group C menin-
OTHER INFECTIONS
gococcus, and a group B meningococcus caused 
the infection in the 14-year-old. In September–Oc-
tober, three adults aged 42, 49 and 52 years and 
one under 12-month-old child contracted a menin-
gococcal infection in Helsinki. The 49-year-old 
and the under 12-month-old patient had infections 
caused by B group meningococci of different sub-
types, the infection in the 52-year-old was caused 
by a group C meningococcus, and the infection 
in the 42-year-old was caused by an unidentiﬁed 
meningococcus (Table 9).
MMR DISEASES (MORBILLI, PAROTITIS EPIDEMICA, 
RUBELLA)
Not a single case of measles or rubella was noti-
ﬁed in 2007. Six cases of mumps were notiﬁed. 
Two patients were under 20 years of age and four 
were adults. In one unvaccinated 17-year-old pa-
tient the source of infection could not be identi-
ﬁed. The other ﬁve patients had contracted the 
disease abroad. 
Measles, mumps and rubella (the MMR dis-
eases) are typical children’s diseases caused by vi-
ruses. Their prevention in Finland was initiated 
by launching the MMR vaccination programme in 
1982. As a result of the programme, endemic cases 
have not been diagnosed in Finland since the mid-
1990s.  In the past 10 years, nearly all diagnosed 
MMR cases were acquired in a country where 
MMR diseases still occur. 
PUUMALA VIRUS (EPIDEMIC NEPHROPATHY)
There were 1,726 notiﬁed cases of Puumala virus 
in 2007, which is about the same as in 2006. Epi-
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Table 9. Meningococcal infections by serogroup, 1995–2007
Year Group A Group B Group C Group Y Group 
W135
Unknown Total
1995 - 50 22 - - 6 78
1996 - 59 15 3 - 2 79
1997 - 36 5 3 - 2 46
1998 - 44 7 2 - 1 54
1999 - 35 9 8 1 5 58
2000 - 30 11 2 3 2 48
2001 - 34 9 4 1 3 51
2002 - 36 6 4 1 2 49
2003 - 28 5 6 - 2 41
2004 - 29 5 4 2 4 44
2005 - 33 1 3 - 3 40
2006 - 38 5 1 - 1 45
2007 - 29 8 5 - 1 43
demic nephropathy has its highest incidence in 
November–December. The number of cases var-
ies, depending on the virus reservoir and the size 
of the bank vole population. The variation follows 
a three-year cycle so that two abundant winters 
(such as 2004 and 2005) are followed by a quieter 
November–December.  The latest quiet winter was 
2006, with about 400 Puumala virus cases notiﬁed 
in November–December. In 2007, the end of the 
year was less quiet again, with 597 Puumala virus 
cases notiﬁed in November–December. The inci-
dence was lowest in March–May. 
In 2007, the incidence rates were highest in the 
Kainuu hospital district (250/100,000) and Lap-
land hospital district (179/100,000). In typical high 
incidence regions the ﬁgures were slightly low-
er, 79/100,000 in Easthern Savo and 57/100,000 
in Southern Savo. More than half of all the cases 
were diagnosed in 35–59-year-olds. Sixty per cent 
of all epidemic nephropathy patients were men 
(Figure 13).
Figure 13. Incidence of Puumala virus cases by
hospital district 2007
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TICK-BORNE ENCEPHALITIS (TBE)
Twenty cases of TBE were notiﬁed to the Nation-
al Infectious Diseases Register in 2007. The ﬁg-
ure is slightly higher than in 2006. The number 
of TBE cases in Finland has ranged from 12 to 41 
per year. The cases notiﬁed in 2007 were diag-
nosed between May and October, with the high-
est frequency in June–August. Before the vaccina-
tion campaign initiated on Åland in 2006, about 
two thirds of the cases were diagnosed in persons 
living on Åland. Five persons contracted TBE on 
Åland in 2007, which makes up 25 per cent of all 
cases. One TBE patient living on Åland had re-
ceived appropriate vaccinations. 
The patient’s place of residence is recorded 
in the National Infectious Diseases Register, which 
may be different from the place of contracting TBE. 
In order to identify the place of acquisition, an in-
fectious disease specialist from the National Public 
Health Institute interviewed patients with TBE diag-
nosed in 2007 and/or studied their patient records. 
One patient contracted the infection in Närpiö, far 
from the well-known endemic TBE regions Kokko-
la and Turku archipelago. Three patients contracted 
TBE in the Kokkola region and two in the Lappeen-
ranta region. Nine patients had contracted the dis-
ease outside of their place of residence; six on Åland 
and three in the Turku archipelago.
 TULAREMIA (FRANCISELLA TULARENSIS)
About 400 cases of tularemia (8/100,000) were no-
tiﬁed to the National Infectious Diseases Register 
in 2007. The high incidence is associated with a 
tularemia outbreak; normally about 100 cases are 
reported each year (1–2/100,000). Previous signiﬁ-
cant tularemia outbreaks occurred in 1995, 1996, 
2000, 2003 and 2006.
The incidence was highest (81/100,000) in 
the Northern Bothnia hospital district, where tu-
laremia is endemic. Typical top incidence districts 
had considerably lower rates, 8/100,000 in Cen-
tral Finland and 3/100,000 in Southern Bothnia. In 
2007, about half of the patients were men. Infec-
tions were diagnosed in all age groups, most fre-
quently in 35–65-year-olds. The majority of cases 
were diagnosed between August and September.
Tularemia is mainly transmitted by mosqui-
toes. When the infection is transmitted from an 
insect to a human, the site of the bite becomes 
red, swollen and sore, and it develops into an ul-
cer.  The infection spreads into local lymph glands 
(ulcero-glandular form). The disease may also be 
transmitted through airways or through a direct 
contact with an ill animal.
POGOSTA DISEASE (SINDBIS VIRUS)
Pogosta disease is caused by the Sindbis virus. 
Since 2004 the number of cases has remained ex-
ceptionally low. There were 30 notiﬁed cases in 
2007 (0.6/100,000). The majority of cases were re-
ported in August–September in Eastern and West-
ern Finland and the province of Oulu. Extensive 
Pogosta disease outbreaks occur in Finland with 
seven year intervals, with the latest outbreak in 
2002.
BORRELIA (LYME DISEASE)
Borrelia cases increased since 2004. There were 
1,330 notiﬁed cases in 2007 (25/100,000). The 
incidence was once again highest on Åland 
with more than 500 cases, making up near-
ly 40 per cent of all borrelia cases in Finland 
(1,938/100,000). As earlier, the occurrence  was 
highest in autumn from August to November. The 
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majority of cases (72%) were diagnosed in over 
45-year-olds (Figure 14).
MALARIA
In 2007, malaria was diagnosed in 21 patients in 
Finland, additionally there was one diagnosed 
vivax malaria relapse. There were 14 Plasmodi-
um falciparum cases, three P. vivax cases, one P. 
ovale case, one P. malariae case and one case with 
P.falciparum + P.vivax mixed infection. Further-
more, one case with P. knowlesii infection was di-
agnosed. 
Fifteen infections (71%) were acquired in Af-
rica. Nine patients were Finns and 12 were for-
eigners. Thirteen patients were permanent resi-
Figure 14. Incidence of borrelia cases by hospital
district 2007
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dents of Finland. Seven patients were native Finns 
who had taken a short trip of less than six months 
to a malaria region, and one was a Finn residing in 
a malaria region. Three patients were immigrants 
from malaria regions who had visited their former 
home country. Nine were refugees who had taken 
ill immediately after arriving in Finland, and one 
was a visitor to Finland.
The number of malaria cases, the countries 
of acquisition and the risk groups have remained 
approximately the same in recent years. Of the 
nine refugees diagnosed with malaria, ﬁve were 
members of a Liberian family arriving from Sierra 
Leone and three were Myanmar refugees arriv-
ing from Thailand. The majority of the 21 malar-
ia patients had taken no malaria prophylaxis at all 
or had taken it irregularly. As regards the native 
Table 10. Malaria cases in Finland in 2007 by 
country of acquisition
Continent Country Cases
Asia Thailand 3
Malaysia 1
Myanmar 0
Total 4
Africa Liberia 1
Nigeria 3
Gambia 3
Sierra Leone 5
Congo 1
Uganda 1
Burkina Faso 1
Total 15
Oceania Papua New Guinea 1
Total 1
South America Dominican Republic 1
Total 1
Total 21
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Finnish patients, three of them had contracted ma-
laria in Gambia. One infection was contracted in 
the Dominican Republic in a region where malaria 
does not normally occur. One Finnish tourist who 
had visited the jungle in Malaysia was diagnosed 
with a P. knowlesii infection. This is a plasmodium 
species that causes malaria in monkeys but has re-
cently been reported to cause malaria in humans 
in Malaysia. The Finnish patient is the second 
tourist reported to have acquired a P. knowlesii in-
fection.
BLOOD AND CSF FINDINGS IN CHILDREN
Blood culture ﬁndings in children
In 2007, the number of cases with blood culture in 
children under 15-years-old  remained at the same 
level as in 2004–2006, with 669 notiﬁed cases. Half 
of the cases were diagnosed in under 1-year-olds. 
In under 1-year-olds, Staphylococcus epider-
midis and other coagulase negative staphylococci 
caused about 40% of the cases with blood culture 
ﬁndings. These infections are typical in newborn 
babies in intensive care, and they usually occur 
later than three days after birth (‘late-onset sep-
sis’). The second most common cause was Strep-
tococcus agalactiae (Group B streptococcus, GBS). 
It is typically contracted from the mother’s birth 
canal during labour and causes an infection in the 
newborn baby during the ﬁrst days of life (‘early-
onset sepsis’). Other common causes of infection 
were Escherichia coli, Staphylococcus aureus and 
Streptococcus pneumoniae. Methicillin-resistant S. 
aureus (MRSA) strains were not found among the 
notiﬁed cases. The proportion of enterococci in 
blood ﬁndings in infants was clearly lower in 2007 
(2%) than in the ﬁve preceding years (4–6%). 
S. pneumoniae was the most common ﬁnd-
ing in 1–14-year-olds, covering more than a third 
of the notiﬁed cases in this age group. It was fol-
lowed by coagulase negative S. aureus and E. coli. 
One of the notiﬁed S. aureus cases was caused by 
MRSA.
Table 11. Blood culture ﬁndings 1995–2007, infants (under 1 years of age)
Microbe/ microbial group 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Staphylococcus, other than aureus 57 84 76 99 112 81 146 129 142 131
Streptococcus agalactiae 48 42 38 41 46 37 45 73 55 51
Escherichia coli 48 39 43 39 40 39 37 41 44 42
Staphylococcus aureus 33 29 17 17 24 21 32 32 37 25
Streptococcus pneumoniae 17 16 28 19 17 25 28 26 27 21
Streptococcus viridans -group 6 10 6 10 8 12 15 12 10 9
Enterococcus faecalis 11 7 4 6 11 11 9 15 22 8
Enterobacter species 7 10 6 6 6 6 5 3 13 8
Klebsiella species 8 10 9 8 7 8 9 9 8 6
Bacillus 1 - 1 2 - 1 2 2 1 4
Other bacteria 41 35 37 22 35 28 36 17 27 28
Bacteria, total 277 282 265 269 306 269 364 359 386 333
Fungi 3 16 12 11 18 4 3 5 4 4
Total number of cases 280 298 277 280 324 273 367 364 390 337
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Table 12. Blood culture ﬁndings 1998–2007, children (1–14 years)
Microbe/microbial group 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Streptococcus pneumoniae 60 61 72 76 92 94 88 101 99 114
Staphylococcus, other than aureus 34 52 63 44 54 46 34 54 48 51
Staphylococcus aureus 48 57 42 35 58 47 58 41 37 42
Streptococcus viridans -group 26 19 18 22 12 12 18 24 24 23
Streptococcus pyogenes 10 11 9 9 10 12 4 - 9 13
Escherichia coli 13 14 20 5 13 13 15 10 16 12
Klebsiella species 3 4 2 2 6 4 5 10 3 6
Fusobacterium species 2 5 4 1 3 - 1 2 3 5
Salmonella, other than Typhi 2 4 1 1 1 1 1 1 2 5
Enterococcus faecium - - 2 2 4 1 2 2 3 4
Other bacteria 53 61 61 48 55 59 44 72 49 53
Bacteria, total 251 288 294 245 308 289 270 317 293 328
Fungi 3 7 5 1 3 3 1 1 5 4
Total number of cases 254 295 299 246 311 292 271 318 298 332
Table 13. Cerebrospinal ﬂuid culture ﬁndings 2002–2007, infants (under 1 year of age)
Microbe/microbial group 2002 2003 2004 2005 2006 2007
Streptococcus agalactiae 5 1 10 7 7 6
Streptococcus pneumoniae 3 6 8 3 1 4
Staphylococcus, other than aureus 8 4 5 4 3 2
Neisseria meningitidis 1 2 4 - 1 2
Enterococcus faecalis - 1 1 - 2 1
Other bacteria 5 7 9 2 5 4
Bacteria, total 22 21 37 16 19 18
Fungi - - - - - -
Total number of cases 22 21 37 16 19 18
Table 14. Cerebrospinal ﬂuid culture ﬁndings 2002–2007, children (1–14 years)
Microbe/microbial group 2002 2003 2004 2005 2006 2007
Neisseria meningitidis 7 4 4 5 7 5
Streptococcus pneumoniae 2 10 2 1 5 5
Staphylococcus aureus 1 2 2 - - 2
Staphylococcus, other than aureus 10 3 6 4 - 1
Streptococcus viridans -group - 1 1 - 2 -
Other bacteria 10 5 4 8 4 -
Bacteria, total 30 25 19 18 18 13
Fungi - - 1 - - -
Total number of cases 30 25 20 18 18 13
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Coagulase negative staphylococci caused 
nearly a third of all cases diagnosed in children, 
the situation being similar since 2001. Intensive 
care and associated interventions, particularly in-
dwelling foreign bodies, such as central venous 
catheters, often constitute the predisposing factor 
for infections caused by these bacteria. Compared 
with recent years, there were no signiﬁcant chang-
es in children’s blood ﬁndings. Fungi constituted 
only one per cent of the ﬁndings.
Cerebrospinal ﬂuid ﬁndings in children
The number of cases with bacterial and fungal 
ﬁndings from CSF in children has remained at a 
very stable level since 1995.  About half of the cas-
es are diagnosed in children under 12 months of 
age. In 2007 there were altogether 32 notiﬁed cas-
es in under 15-year-olds. 
The most common ﬁnding in children under 
12 months of age was S. agalactiae (GBS) with six 
cases. Meningitides due to GBS are usually late-
onset infections in infants, often with an unidenti-
ﬁed source of origin; the mother has been found to 
carry GBS in only about half of the cases. The next 
most common ﬁnding was S. pneumoniae with 
four notiﬁed cases. S. epidermidis and meningo-
coccus were both notiﬁed twice. All the other cas-
es were sporadic ﬁndings.
Meningococcus and pneumococcus were 
the most common ﬁndings in 1–14-year-olds, 
both with ﬁve notiﬁed cases. S. aureus was no-
tiﬁed twice and S. epidermidis once. The total 
number of cases in this age group – and in under 
15-year-olds overall – was slightly lower than in 
2002–2006.
BLOOD AND CSF FINDINGS IN ADULTS
Blood culture ﬁndings in adults
The total number of cases with blood culture ﬁnd-
ings in adults has grown steadily in recent years. 
In 2007, there were nearly 10,000 cases. Gram-
positive bacteria are still more common in the 
Table 15. Blood culture ﬁndings 1998–2007, working-age population (15–64 years)
Microbe/microbial group 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Escherichia coli 495 547 532 613 580 645 707 780 797 838
Staphylococcus aureus 340 389 394 437 457 445 486 457 564 544
Staphylococcus, other than aureus 319 347 402 406 444 400 421 399 401 407
Streptococcus pneumoniae 283 298 310 343 330 406 387 376 346 353
Klebsiella species 106 114 115 114 134 121 159 184 145 159
Streptococcus pyogenes 63 81 84 60 93 78 93 76 105 133
Streptococcus viridans -group 91 115 117 116 104 121 141 141 130 118
Streptococcus, other beta-haemolytic 59 64 59 66 78 79 102 96 127 117
Enterococcus faecalis 57 76 67 95 98 84 80 100 83 101
Streptococcus agalactiae 55 60 63 76 78 68 64 99 76 83
Other bacteria 690 652 686 748 662 681 694 795 802 829
Bacteria, total 2558 2743 2829 3074 3058 3128 3334 3503 3576 3682
Fungi 62 58 56 71 54 80 71 66 80 84
Total number of cases 2620 2801 2885 3145 3112 3208 3405 3569 3656 3766
I N F E C T I O U S  D I S E A S E S  I N  F I N L A N D  2 0 0 7
40
Table 16. Blood culture ﬁndings 1998–2007, aged population (65 years and more)
Microbe/microbial group 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Escherichia coli 967 1012 1033 1178 1213 1314 1466 1623 1706 1761
Staphylococcus aureus 296 337 397 398 449 466 483 483 601 567
Staphylococcus, other than aureus 216 281 349 361 363 343 370 402 395 415
Klebsiella species 177 167 201 241 230 252 342 339 326 340
Streptococcus pneumoniae 185 178 189 216 200 241 239 229 270 293
Enterococcus faecalis 116 119 143 142 149 146 192 183 202 217
Pseudomonas aeruginosa 94 116 119 132 148 148 138 151 154 189
Streptococcus, other beta-haemolytic 73 97 87 105 100 123 135 140 174 171
Bacteroides fragilis -group 81 99 96 104 96 117 120 135 119 135
Enterococcus faecium 41 43 60 61 48 75 96 73 108 129
Other bacteria 606 596 677 758 721 774 863 924 965 986
Bacteria, total 2852 3045 3351 3696 3717 3999 4444 4682 5020 5203
Fungi 43 51 68 71 71 113 77 68 76 83
Total number of cases 2895 3096 3419 3767 3788 4112 4521 4750 5096 5286
working-age population (15–64-year-olds) and 
gram-negative bacteria among those aged 65 or 
more. Anaerobic bacteria constituted nearly ﬁve 
per cent and fungi about two per cent of all blood 
culture positive ﬁndings. 
In the working-age population, the most com-
mon bacterial ﬁnding was Escherichia coli, con-
stituting about twenty per cent of all cases. It was 
followed by Staphylococcus aureus, coagulase neg-
ative staphylococci and Streptococcus pneumoniae.
E. coli was also the most common blood 
culture ﬁnding among patients aged 65 years or 
more, representing a third of all ﬁndings. The next 
most common bacterial ﬁndings were S. aureus, 
coagulase negative staphylococci, Klebsiella spe-
cies and S. pneumoniae.
The number of cases with group A strepto-
cocci (Streptococcus pyogenes) increased among 
the working-age population. The prevailing emm 
types have partly been replaced with new, less 
Table 17. Cerebrospinal ﬂuid culture ﬁndings 2002–2007, working-age population (15–64 years)
Microbe/microbial group 2002 2003 2004 2005 2006 2007
Staphylococcus, other than aureus 42 28 40 48 44 24
Neisseria meningitidis 19 15 11 15 20 16
Staphylococcus aureus 6 10 17 10 9 16
Streptococcus pneumoniae 18 26 21 15 17 13
Pseudomonas, other than aeruginosa 6 6 11 5 5 5
Other bacteria 44 26 27 47 51 48
Bacteria, total 135 111 127 140 146 122
Fungi 2 1 6 2 3 6
Total number of cases 137 112 133 142 149 128
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Table 19.  S. pyogenes blood ﬁndings according to emm-type, 2004–2007
Cases notiﬁed to 
the National In-
fectious Disease 
Register
Strains 
examined
emm1 emm28 emm84 other NT
2004 130 6 (4,6%) 46 (35,4%) 0 (0,0)  72 (55,4%) 6 (4,6%)
2005 113 9 (8,0%) 22 (19,5%) 1 (0,9%) 79 (69,9%) 2 (1,8%)
2006 163 25 (15,3%) 33 (20,2%) 24 (14,7%) 70 (42,9%) 11(6,7%)
2007 205 58 (28,3%) 26 (12,7%) 32 (15,6%) 84 (41,0%) 5 (2,4%)
known types, but the emm 1 type (previously 
T1M1) that caused severe illnesses in the past has 
also increased. Since 1995, the number of blood 
culture conﬁrmed pneumococcal infections has 
been on the rise among the elderly, and in 2007 
the number of ﬁndings reached a new record (293) 
(Table 19). 
Among the working-age population, the 
number of Candida albicans ﬁndings has tripled 
and among over 65-year-olds it has doubled from 
1995 to 2007.
Cerebrospinal ﬂuid ﬁndings in adults
The number of bacterial and fungal ﬁndings in 
adults doubled from 1995 to 2004. After  2004, the 
number of ﬁndings has remained relatively stable. 
In 2007, there was even a slight decrease in the 
number of CSF ﬁndings in the working-age popu-
lation and the elderly. The most common bacterial 
ﬁnding in working-age patients is still coagulase 
negative staphylococcus. As regards actual patho-
gens, meningococcus and 
S. aureus were equally common, followed by 
pneumococcus.
Coagulase negative staphylococcus was also 
the most common culture ﬁnding in patients aged 
65 years or more. It was followed by pneumococ-
cus, Enterococcus faecalis, S. aureus and Listeria 
monocytogenes.
Table 18. Cerebrospinal ﬂuid culture ﬁndings 2002–2007, aged population (65 years and more)
Microbe/microbial group 2002 2003 2004 2005 2006 2007
Staphylococcus, other than aureus 12 9 11 15 12 14
Streptococcus pneumoniae 4 5 4 8 10 4
Enterococcus faecalis 2 3 - 2 2 3
Staphylococcus aureus 2 7 7 5 3 2
Listeria monocytogenes 2 4 2 4 3 2
Other bacteria 20 17 13 12 12 7
Bacteria, total 42 45 37 46 42 32
Fungi 2 - 1 1 2 -
Total number of cases 44 45 38 47 44 32
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